On Thursday, staff from Malvern Panalytical enjoyed a visit from Prince Edward as he toured the company based at Enigma Business Park. The Earl of Wessex was introduced to a number of employees and learned about the roles they play in developing new technologies and services. During a socially distanced tour, he had the chance to ask employees some of his own personal questions.
On display were a number of scientific instruments used by the company’s pharmaceutical customers in developing and manufacturing new drugs and vaccines. Malvern also helps in assisting pharmaceutical organisations in assuring the quality of vaccines and treatments. Andrew Heath, the chief executive of the firm’s owners Spectris said of the Earl’s visit:
“It has been our pleasure to welcome Prince Edward to our Malvern development and manufacturing facility and to explain how Malvern Panalytical’s people, products and services are assisting the global effort to fight COVID-19.
“We are immensely proud of the role the team here is playing in applying its technical and scientific expertise to help alleviate this humanitarian crisis.”
Mark Fleiner, the president of Malvern Panalytical discussed the companies successes in the last year and how Malvern has made a real contribution to the development of protein antigen and mRNA-based COVID vaccines.
“Malvern Panalytical provides the instruments and expertise to support robust and rapid vaccine development and assist pharmaceutical organizations in assuring the quality of vaccines and other treatments.”
Fleiner went on to add: “It makes us proud to see how we are helping our customers create a better world in all sorts of markets. From renewable energy and sustainable building materials, all the way through to nutritious foods and critically important medicines, Malvern Panalytical is making a positive impact.”
Worldwide, Malvern has employed more than 2,200 people. It was formed by the merger of Malvern Instruments and PANalytical in 2017.
